Cargando…
ACE-I/ARB Therapy prior to Contrast Exposure: What Should the Clinician Do?
Contrast-induced nephropathy (CIN) is now one of the three leading causes of acute kidney injury in the world. A lot is known about the risk factors of CIN, yet it remains a major cause of morbidity, end stage renal disease, prolonged hospital stay, and increased costs as well as a high mortality. M...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3925541/ https://www.ncbi.nlm.nih.gov/pubmed/24605330 http://dx.doi.org/10.1155/2014/423848 |
_version_ | 1782303873020461056 |
---|---|
author | Kalyesubula, Robert Bagasha, Peace Perazella, Mark A. |
author_facet | Kalyesubula, Robert Bagasha, Peace Perazella, Mark A. |
author_sort | Kalyesubula, Robert |
collection | PubMed |
description | Contrast-induced nephropathy (CIN) is now one of the three leading causes of acute kidney injury in the world. A lot is known about the risk factors of CIN, yet it remains a major cause of morbidity, end stage renal disease, prolonged hospital stay, and increased costs as well as a high mortality. Many patients undergoing contrast-based radiological investigations are treated with angiotensin converting inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs) for their cardiac and renal benefits and their known mortality benefits. However, controversy exists among clinicians as to whether ACE-Is and ARBs should be continued or discontinued prior to contrast media exposure. In this paper we review the current evidence on ACE-I/ARB therapy for patients undergoing procedures involving use of contrast media and provide recommendations as to whether these drugs should be continued or held prior to contrast exposure. |
format | Online Article Text |
id | pubmed-3925541 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-39255412014-03-06 ACE-I/ARB Therapy prior to Contrast Exposure: What Should the Clinician Do? Kalyesubula, Robert Bagasha, Peace Perazella, Mark A. Biomed Res Int Review Article Contrast-induced nephropathy (CIN) is now one of the three leading causes of acute kidney injury in the world. A lot is known about the risk factors of CIN, yet it remains a major cause of morbidity, end stage renal disease, prolonged hospital stay, and increased costs as well as a high mortality. Many patients undergoing contrast-based radiological investigations are treated with angiotensin converting inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs) for their cardiac and renal benefits and their known mortality benefits. However, controversy exists among clinicians as to whether ACE-Is and ARBs should be continued or discontinued prior to contrast media exposure. In this paper we review the current evidence on ACE-I/ARB therapy for patients undergoing procedures involving use of contrast media and provide recommendations as to whether these drugs should be continued or held prior to contrast exposure. Hindawi Publishing Corporation 2014 2014-01-29 /pmc/articles/PMC3925541/ /pubmed/24605330 http://dx.doi.org/10.1155/2014/423848 Text en Copyright © 2014 Robert Kalyesubula et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Kalyesubula, Robert Bagasha, Peace Perazella, Mark A. ACE-I/ARB Therapy prior to Contrast Exposure: What Should the Clinician Do? |
title | ACE-I/ARB Therapy prior to Contrast Exposure: What Should the Clinician Do? |
title_full | ACE-I/ARB Therapy prior to Contrast Exposure: What Should the Clinician Do? |
title_fullStr | ACE-I/ARB Therapy prior to Contrast Exposure: What Should the Clinician Do? |
title_full_unstemmed | ACE-I/ARB Therapy prior to Contrast Exposure: What Should the Clinician Do? |
title_short | ACE-I/ARB Therapy prior to Contrast Exposure: What Should the Clinician Do? |
title_sort | ace-i/arb therapy prior to contrast exposure: what should the clinician do? |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3925541/ https://www.ncbi.nlm.nih.gov/pubmed/24605330 http://dx.doi.org/10.1155/2014/423848 |
work_keys_str_mv | AT kalyesubularobert aceiarbtherapypriortocontrastexposurewhatshouldthecliniciando AT bagashapeace aceiarbtherapypriortocontrastexposurewhatshouldthecliniciando AT perazellamarka aceiarbtherapypriortocontrastexposurewhatshouldthecliniciando |